Lipid Disorders and Coronary Heart Disease Risk
Dr. Gotto joined Cornell University Medical College after serving 25 years at Baylor College of Medicine in Houston, Texas, where he and his associates were the first to achieve the complete synthesis of a plasma apolipoprotein (apo C-I). They also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis and cardiovascular disease, as well as the structure of apo B-48. Dr. Gotto's research interests include the structure, metabolism, and function of the plasma lipoproteins and apolipoproteins and their relation to atherosclerosis; clinical disorders of lipid transport, including hyperlipoproteinemias and hypo-lipidemias; and the pathology of atherosclerosis and coronary heart disease.
Dr. Gotto has been involved with numerous lipid-modifying intervention trials, including serving as principal investigator for the Baylor College of Medicine branch of the landmark Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) in the 1980s and for the Lipoprotein and Coronary Atherosclerosis Study (LCAS) in the 1990s. These trials have offered compelling evidence that modifying serum cholesterol concentrations can reduce clinical coronary event rates and slow the progression of atherosclerotic disease.